Protagenic Therapeutics Completes $2.0 Million Convertible Note Financing

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="center"><strong><em>Capital to be Used to Complete IND Filing and Commence Phase I/II Clinical Trial for Lead Clinical Compound PT00114</em></strong><br /></p><p align="justify">NEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (OCTQB: PTIX) announced today that it has completed a convertible note financing, raising its target...